![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, December 30, 2009 1:11:28 PM
44.) Imaging 3 (IMGG.OB) ($0.64) is currently awaiting a decision by the FDA for marketing clearance of their DViS (Dominion Volumetric Imaging Scanner), which is a patented breakthrough mobile fluoroscopy technology that produces high-quality 3D images in real time by utilizing photo-fluoroscopy. On a 9/24/09 conference call, CEO Dean Janes announced that the next submission to the FDA will take place on 9/30/09. The CEO has stated that a response from the Agency could come within 15-30 days post-submission (as early as the end of September), but that all of his timelines were only estimates and not formal FDA deadlines and subject to change and/or delays. The CEO provided guidance that the Company may be 1-2 filings away from FDA marketing clearance based on his estimation and further replies may be necessary to respond to the Agency for a final decision by year-end as the ultimate goal so that 12/31/09 is the estimated date for this entry.
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM